BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.5000
-0.0700 (-2.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.5700
Open2.5600
Bid0.0000 x 21500
Ask0.0000 x 800
Day's Range2.4900 - 2.6800
52 Week Range2.4900 - 9.9500
Volume1,326,811
Avg. Volume1,765,357
Market Cap276.095M
Beta (3Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-1.1540
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.71
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of BCRX earnings conference call or presentation 6-Aug-19 12:30pm GMT

    Q2 2019 BioCryst Pharmaceuticals Inc Earnings Call

  • Biocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Biocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript

    BCRX earnings call for the period ending June 30, 2019.

  • BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates

    BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    BioCryst Reports Second Quarter 2019 Financial Results

    —New drug application for once-daily oral BCX7353 for prophylaxis of hereditary angioedema attacks on-track for submission in Q4 2019— —Data from ongoing Phase 1 trial of oral.

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees options to purchase an aggregate of 42,000 shares of BioCryst common stock on July 31, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $3.17 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.

  • Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline

    BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    BioCryst to Report Second Quarter 2019 Financial Results on August 6

    RESEARCH TRIANGLE PARK, N.C., July 23, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2019 financial.

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees options to purchase an aggregate of 33,000 shares of BioCryst common stock on June 30, 2019, and granted Megan Sniecinski, the company’s new chief business officer, the option to purchase an aggregate of 500,000 shares of BioCryst common stock on July 1, 2019, in each case as inducements material to each employee entering into employment with BioCryst. The June 30, 2019 options have an exercise price of $3.79 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date, and the July 1, 2019 options have an exercise price of $3.71 per share, which is equal to the closing price of BioCryst common stock on the grant date.

  • GlobeNewswire

    BioCryst Appoints Megan Sniecinski Chief Business Officer

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced the appointment of Megan Sniecinski as chief business officer. Ms. Sniecinski joins BioCryst from PTC Therapeutics, where she served as senior vice president of business operations and program management since June 2017. Over nearly five years at PTC, Ms. Sniecinski played a key role in supporting the diversified growth of PTC’s rare disease pipeline and transformation into a global, fully-integrated biopharmaceutical company.

  • GlobeNewswire

    Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has begun enrollment of a Phase 1 trial of BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, for the treatment of complement-mediated diseases. “An oral Factor D inhibitor would meet a significant unmet medical need for patients with many complement-mediated diseases. The preclinical profile of BCX9930 showed high potency, excellent specificity for Factor D, complete suppression of complement-mediated hemolysis after oral dosing, and a wide safety margin, so we look forward to seeing the clinical results from this Phase 1 trial,” said Dr. William Sheridan, chief medical officer of BioCryst.

  • Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy?
    Insider Monkey

    Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has experienced […]

  • Thomson Reuters StreetEvents

    Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT

    Q1 2019 BioCryst Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., May 31, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies 2019 Healthcare.

  • Here's Why BioCryst Pharmaceuticals Is Soaring Today
    Motley Fool

    Here's Why BioCryst Pharmaceuticals Is Soaring Today

    A hedge fund disclosed a sizable stake in the company.

  • Benzinga

    The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...

  • Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today
    Motley Fool

    Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today

    Tough conditions for these companies left them out of the day's rally.

  • In less than six hours today, this Durham company's stock has dropped 50 percent
    American City Business Journals

    In less than six hours today, this Durham company's stock has dropped 50 percent

    One Triangle drug-maker is feeling confident following a successful Phase III trial – despite some less confident investors pulling the stock down nearly 50 percent.

  • Here's Why BioCryst Pharmaceuticals Collapsed Today
    Motley Fool

    Here's Why BioCryst Pharmaceuticals Collapsed Today

    This is a case study of when a successful phase 3 trial isn't successful enough.

  • Benzinga

    BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial

    BioCryst announced Tuesday that a Phase 3 study dubbed APeX-2, which is evaluating once-daily, oral BCX7353 — a selective inhibitor of plasma kallikrein — in preventing hereditary angioedema, or HAE, attacks, met the primary endpoint for both the 110mg and 150mg dose levels. The primary efficacy endpoint is the rate of investigator-confirmed angioedema attacks over 24 weeks of study drug administration. The 110mg dose of BCX7353 reduced the HAE attack rate by 30 percent compared to placebo and the 150mg dose reduced the attack rate by 44 percent.

  • GlobeNewswire

    BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial

    Fifty percent of patients receiving 150 mg BCX7353 in APeX-2 had a ≥ 70 percent reduction in their HAE attack rate compared to baseline, compared to 15 percent of placebo patients (p=0.002). In patients on the 150 mg dose with a baseline attack rate of

  • Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?
    Zacks

    Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?

    Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.

  • GlobeNewswire

    BioCryst to Present at Bank of America Merrill Lynch Health Care Conference

    RESEARCH TRIANGLE PARK, N.C., May 10, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch.

  • GlobeNewswire

    BioCryst Completes Phase 1 Clinical Trial of Galidesivir

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers.  In the trial, galidesivir was generally safe and well tolerated. This placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in four single-dose cohorts of 5mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg, with a total of 24 volunteers receiving galidesivir by IV infusion. Drug exposures (Cmax and AUC) at the highest dose were 20,500 ng/mL and 44,600 hr.ng/mL, similar to or greater than drug exposures needed in nonclinical galidesivir treatment experiments in Marburg virus disease and Yellow Fever.